FXL First Trust Technology AlphaDEX Fund
Profitability Metrics
Valuation Metrics
Growth & Cash Flow
Price Change
Top 10 Holdings
| Stock Ticker | Weight |
|---|---|
| VRT | 2.67% |
| AMAT | 2.32% |
| ARW | 2.29% |
| MTSI | 2.26% |
| CRUS | 2.16% |
| LRCX | 2.16% |
| KLAC | 2.10% |
| AKAM | 1.86% |
| AVT | 1.80% |
| SAIC | 1.74% |
ETF Analysis
Fund Overview
First Trust Technology AlphaDEX Fund (FXL) currently reports 102 stock positions (subject to change), placing it in the index-like in breadth range by holdings breadth. The top line-up is VRT (2.67%), AMAT (2.32%), ARW (2.29%), with VRT as the largest single weight at 2.67%. Together, the top three holdings account for 7.28%, which reflects a construction where the top positions carry meaningful but not outsized influence on aggregate returns. In aggregate, the construction reflects a balance between directional conviction and the diversification benefits that come from a broader holding set.
Profitability & Capital Efficiency
On the question of capital productivity, ROIC is 24.95%, WACC is 10.44%, and the economic spread is 14.51%. On balance, the economic spread is positive and meaningful, suggesting the underlying holdings are building rather than eroding intrinsic value. Supporting metrics show ROE at 25.00% and ROA at 7.96%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.
Valuation
Assessed on a multiple basis, trailing P/E of 22.84, forward P/E of 12.40, PEG of 1.54. The difference between trailing and forward multiples is significant, suggesting investors are paying today for earnings that have not yet been fully delivered. Growth-adjusted, the multiple is in an acceptable range — the portfolio is neither pricing in perfection nor offering a meaningful valuation discount. The portfolio's holdings carry a current ratio of 2.71, pointing to strong short-term financial health. Overall, the valuation setup reads as a balance between expected growth and execution risk, with liquidity acting as an important stabilizer if macro conditions become less favorable.
Margins & Cash Generation
The margin stack reads as follows: gross margin sits at 50.91%, operating margin at 17.25%, and free cash flow margin at 21.11%. The gross margin reading points to holdings with solid but not outsized pricing power relative to direct costs. The portfolio's operating margins are solid, pointing to holdings where overhead management is a relative strength. FCF margins are constructive here, reflecting holdings that generate cash reliably after reinvestment requirements. The margin profile is a mixed read — some holdings are clearly well-run, but the aggregate numbers point to a basket that is not uniformly high-quality.
Growth & Forward Outlook
Where growth and expectations intersect, the estimated 12-month price change of 24.68%, where analyst assumptions support a moderate upside case if execution remains steady, while TTM revenue growth of 19.74% suggesting the portfolio's holdings are growing revenues at a measured, sustainable pace. The projected 12-month EPS growth rate of 84.2% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. Both signals are useful lenses, but they tend to diverge most sharply near inflection points in both business fundamentals and market sentiment. The durability of both the operating trend and analyst optimism will determine whether the current setup translates into measurable near-term returns. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.
Conclusion
Strong BuyPutting all the pieces together, the fundamental picture is one of the more convincing setups in these metrics — strong capital returns, reasonable pricing, and a healthy forward outlook.
These findings are based solely on the metrics presented and do not constitute an investment recommendation. Always perform your own due diligence before committing capital.